Abstract 1579P
Background
Worldwide, AYA care for patients < 25 years is mostly delivered by paediatric oncologists. For the whole range of patients at AYA age (15- 39 years) there is a need for AYA care in adult oncology practices. In 2014, a national AYA network with central coordination, started in the Netherlands (NL) in 7 university medical centres and a cancer centre, with the aim to extend to a nationwide network in the adult oncology environment. This network, co-designed by healthcare professionals (HCPs), patients and caregivers, has evolved towards a data driven learning healthcare system and may be a model for other countries as well.
Methods
From its start, with very limited resources, annual plans were made with lean deliverables, topics on AYA care domains were addressed, (mandatory) teaching modules for HCPs have been developed, and AYA research projects were written with the aim to constantly feed data into the educational and care initiatives of the network.
Results
In ten years, the number of hospitals delivering AYA care has expanded to 75; since 2024 AYA care and network-management is reimbursed by healthcare insurance companies. Research projects have been awarded from the Dutch Cancer Society, Dutch Scientific Council and EU Horizon program. COMPRAYA – a prospective study to collect clinical, biological and psychosocial data, GENAYA - a collection of whole genome sequencing data, INVAYA and CORDAYA –research projects for AYAs with an uncertain or poor prognosis and SURVAYA investigating AYAs 5-20 years after diagnosis, all generate data to constantly improve AYA care. Our awarded EU project STRONG AYA, with federated data collection running in NL, UK, France, Poland and Italy will generate data for individual countries and will ensure benchmarking to improve AYA care at pan-European level. Results of projects are evaluated regularly by master and PhD students with medical, psychosocial and econometry background and postdoctoral researchers, supervised by the core team. Teaching modules are adapted and developed based on the obtained data.
Conclusions
The model of a learning AYA-healthcare system enables collaborative (inter)national data driven initiatives, which has the advantage to improve AYA care at an (inter)national and local level.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10